VAXDYN

VAXDYN is a private, pre-revenue biotech focused on developing novel vaccines against multi-drug resistant bacterial pathogens, a critical threat in the post-antibiotic era. Its core technology platform transforms an inactivated, LPS-null (endotoxin-free) whole-cell vaccine candidate into multivalent vaccines targeting 'superbugs' like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The company is supported by non-dilutive funding (e.g., CARB-X, EU grants) and is advancing its lead candidate, AcinetoVax, towards clinical development while expanding its pipeline.

Inactivated, LPS-null (endotoxin-free) whole-cell bacterial vaccine platform engineered to display multiple conserved surface antigens for creating multivalent vaccines against antibiotic-resistant gram-negative bacteria.

The AMR vaccine space includes larger pharma (e.g., Pfizer, GSK) and biotechs targeting specific pathogens like Staphylococcus aureus. VAXDYN's focus on a multivalent, endotoxin-free whole-cell approach for gram-negative bacteria differentiates it, but it competes with other platform technologies (e.g., recombinant protein, conjugate vaccines) from companies and academic consortia worldwide.